Systemic and local predictors of medication-related osteonecrosis of the jaw in patients receiving antiresorptive therapy: The Shizuoka Kokuho Database study

CONCLUSION: Predictors of MRONJ differed between antiresorptive dose groups. Oral risk treatment immediately before therapy initiation was consistently associated with higher MRONJ occurrence, suggesting that oral risk conditions near initiation may be important for risk stratification.